Abstract
Abstract Abstract #3057 Introduction: Patients (pts) with ER/PR/HER2 negative advanced breast cancer (triple negative, TN, basal-like) have limited treatment options and a poor prognosis. Ixabepilone (ixa), the first in a new class of antineoplastic agents, showed clinical benefit in combination with capecitabine (C) in 2 large clinical trials in metastatic breast cancer (MBC) pts either resistant to (study 046; JCO, 2007) or pretreated with anthracycline (A) and taxanes (T) (study 048). In 048, ixa + C, compared to C alone, demonstrated significant increases in PFS (HR 0.79 [0.69-0.90]) and ORR (43 vs. 29%). A trend towards increased OS was seen in both 048 (HR 0.90 [0.78-1.03]) and 046 (HR 0.90 [0.77-1.05]), which did not reach statistical significance. Here we present a pooled analysis of efficacy endpoints (ORR, PFS and OS) in pts with TN disease from these 2 phase III studies.
 Methods: 1973 pts with MBC previously treated with A and T were randomized in 2 phase III trials (046 and 048) to receive either ixa (40 mg/m2 IV over 3h Q3w) + C (1000 mg/m2 PO BID x14d Q3w) or C alone (1250 mg/m2 PO BID x14d Q3w). Due to the similarity of the study populations, individual pt data from both studies was pooled to better evaluate treatment effect within pre-planned patient subgroups.
 Results: 443 pts had TN disease in the two studies combined. ORR and PFS were superior in pts receiving combination therapy compared to those on C alone with a trend towards improved survival that did not reach statistical significance.
 
 Conclusions: Ixa + C is the first combination to show statistically significant PFS benefit in pts with advanced TN breast cancer from a pooled analysis of 2 phase III trials. Clinical benefit was consistently seen pts with TN disease in the individual studies as well. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3057.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
